z-logo
open-access-imgOpen Access
<p>The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells</p>
Author(s) -
Ziwei Li,
Bin Li,
Li Li,
Guanying Wang,
Yuanyuan Li,
Ruoqiu Fu,
Yue Ming,
Rui Ni,
Jiming Wang,
George Ye,
Jianhong Chen
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s281397
Subject(s) - jurkat cells , apoptosis , monoclonal antibody , cell culture , microbiology and biotechnology , cancer cell , t cell , cell cycle , biology , cancer research , immune system , chemistry , antibody , immunology , cancer , biochemistry , genetics
Monoclonal antibodies (mAbs) that target the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint have demonstrated substantial clinical benefit for a variety of solid tumors. However, their applications in patients with hepatocellular carcinoma (HCC) are reported with unclear molecular mechanisms. Here, we report a novel mouse anti-human PD-1 mAb that can reverse the immunosuppressive effect of HePG2 cells on Jurkat cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here